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Abstract
Background: Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) can provide
unique data on the transmural extent of scar/viability. We assessed the prevalence of dysfunctional myocardium,
including partial thickness scar, which could contribute to left ventricular contractile dysfunction in patients with
heart failure and ischaemic heart disease who denied angina symptoms.
Methods: We invited patients with ischaemic heart disease and a left ventricular ejection fraction < 50% by
echocardiography to have LGE CMR. Myocardial contractility and transmural extent of scar were assessed using a
17-segment model.
Results: The median age of the 193 patients enrolled was 70 (interquartile range: 63-76) years and 167 (87%) were
men. Of 3281 myocardial segments assessed, 1759 (54%) were dysfunctional, of which 581 (33%) showed no scar,
623 (35%) had scar affecting ≤50% of wall thickness and 555 (32%) had scar affecting > 50% of wall thickness. Of
1522 segments with normal contractile function, only 98 (6%) had evidence of scar on CMR. Overall, 182 (94%)
patients had ≥1 and 107 (55%) patients had ≥5 segments with contractile dysfunction that had no scar or ≤50%
transmural scar suggesting viability.
Conclusions: In this cohort of patients with left ventricular systolic dysfunction and ischaemic heart disease, about
half of all segments had contractile dysfunction but only one third of these had > 50% of the wall thickness
affected by scar, suggesting that most dysfunctional segments could improve in response to an appropriate
intervention.
Keywords: Heart failure, Myocardial infarction, Hibernation, Cardiovascular magnetic resonance imaging, Late gado-
linium enhancement
Background
Ischaemic heart disease (IHD) is a common cause of left
ventricular (LV) systolic dysfunction leading to chronic
heart failure (CHF) [1]. Patients with lower LV ejection
fraction (EF) and more extensive coronary artery disease
have a worse prognosis [2]. LV systolic dysfunction in
patients with IHD may be due to either myocardial
necrosis leading to scar, or to impaired myocardial con-
tractility despite myocardial viability (hibernation or
stunning) [3]. Viable but dysfunctional myocardium can
potentially recover if the ratio of myocardial oxygen
supply to demand can be improved either by coronary
revascularisation or with anti-ischaemic treatment,
although recovery of function may take months or even
years [4-7]. Many hearts are likely to have systolic dys-
function related to a complex substrate including vari-
able quantities of myocardium affected by full or partial
* Correspondence: cbourantas@gmail.com
† Contributed equally
Department of Cardiology, Academic Unit, University of Hull, Postgraduate
Medical Institute, Kingston-upon-Hull, UK
Bourantas et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:53
http://www.jcmr-online.com/content/13/1/53
© 2011 Bourantas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
thickness scar, stunning, hibernation, and reversible
ischemia.
The proportion of patients who have a substantial
volume of myocardium that is dysfunctional but viable
is uncertain [8]. The inconsistencies in available data
may be related to limitations of the imaging methods
conventionally used to detect myocardial viability (myo-
cardial perfusion scintigraphy, positron emission tomo-
graphy and stress echocardiography) or the populations
studied. Cardiovascular magnetic resonance (CMR) with
late gadolinium enhancement (LGE) is a high-resolution
imaging method that can estimate scar volume and
transmurality and provide information regarding myo-
cardial viability. The method is based on the accumula-
tion of paramagnetic contrast (gadolinium) in necrotic
(acute infarction) or scar tissue. Myocardial injury with-
out necrosis or scarring does not lead to LGE despite
the presence of myocardial hibernation/stunning [9-11].
Given the high spatial resolution of CMR, it is possible
to measure not only the number of myocardial segments
affected but also the transmural extent of scar, a cap-
ability unmatched by other imaging techniques. Scars
affecting ≤50% of the thickness of the myocardial wall
appear to predict functional improvement following
revascularisation or medical therapy [11,12].
Revascularisation might lead to improvement in LV
systolic function and improve the clinical state of
patients with CHF. However, the potential for revascu-
larisation is dependent upon the extent of reversible
ischaemia as opposed to scar in the areas to be revascu-
larised. In addition, the extent and distribution of trans-
mural scar may also affect the response to cardiac
resynchronisation therapy (CRT) [13,14]. We therefore
designed the present study to investigate the prevalence
and distribution of scarred myocardium (and assess the
relationship between contractile dysfunction and the
extent of myocardial scar) in an epidemiologically-repre-
sentative group of patients with CHF and IHD, who did
not complain of symptoms of angina and in whom
revascularisation as a treatment option was not excluded
by severe co-morbidities or frailty.
Methods
Study subjects
We prospectively enrolled patients with stable clinical
signs and symptoms of CHF (New York Heart Associa-
tion (NYHA) functional class I to III) due to LV ventri-
cular systolic dysfunction and IHD attending a
community-based heart failure clinic serving a popula-
tion of just over 0.5 million. The diagnosis of heart fail-
ure was based on symptoms and signs assessed by a
cardiologist. Patients with a baseline echocardiogram
showing a LVEF < 50% were considered to have systolic
dysfunction. The diagnosis of IHD was confirmed by a
history of myocardial infarction, coronary revascularisa-
tion or > 50% of luminal diameter coronary stenoses on
angiography [15].
Exclusion criteria were significant primary valvular or
congenital heart disease, a myocardial infarction or
revascularisation during the 12 months prior to recruit-
ment, and conventional contraindications to CMR
(metal in the eye or in the brain, pacemakers or defibril-
lators, and claustrophobia). Patients who reported angi-
nal symptoms were also excluded from the study since
these patients would be expected to have substantial
amounts of viable myocardium subtended by diseased
coronary arteries. Patients with severe co-morbidities or
who were considered too frail for revascularisation were
also excluded.
Patients were first treated with appropriate pharmaco-
logical treatment including diuretics, renin-angiotensin-
aldosterone system (RAAS) inhibitors, b-blockers and
aldosterone antagonists unless contra-indicated or not
tolerated and were seen regularly in a heart failure clinic
to ensure continued optimisation of treatment and were
then referred for CMR. Typically there was a delay
(mean ± standard deviation: 4 ± 5.5 months) between
initial assessment and CMR during which ventricular
function may have improved with therapy. Written
informed consent was obtained in all study patients.
The study complies with the Declaration of Helsinki
and was approved by the local research ethics
committee.
Cardiac magnetic resonance imaging
Patients underwent CMR on a 1.5 Tesla scanner (Signa
CV/i, GE Medical Systems) using ECG-triggered breath-
hold gradient-echo in steady-state acquisition (FIESTA)
imaging. After initial localizing scans, cine LV horizontal
long-axis, vertical long-axis and contiguous short-axis
images covering the LV from apex to base (slice thick-
ness 10 mm) were obtained. The multi-slice short-axis
cine data sets were analyzed by an expert observer
whose reliability and reproducibility has already been
tested (Table 1) [16]. This observer manually traced the
endocardial and epicardial borders in the end-diastolic
and end-systolic frames, in each one of the contiguous
short-axis slices using specialized software (MEDIS, Lei-
den, NL). These borders were then used to calculate LV
end-diastolic volume (EDV), end-systolic volume (ESV),
EF and myocardial mass (MM). The indices of EDV,
ESV and MM were obtained by correcting for body sur-
face area. Wall thickening was assessed blind to the
LGE results by an expert observer using a 17-segment
model as recommended by the American Heart Associa-
tion [17]. The segments were classified as normal or
dysfunctional (mildly hypokinetic, severely hypokinetic,
akinetic or dyskinetic) on the basis of visual assessment.
Bourantas et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:53
http://www.jcmr-online.com/content/13/1/53
Page 2 of 11
The reproducibility and reliability of the observer who
visually evaluated the presence of wall thickening
abnormalities was examined in 30 randomly selected
CMR scans. The observer reviewed the data twice
within 2 months blind to the results of the first scan. A
second observer reviewed the same scans once. Intra-
and interobserver agreement was high with Cohen’s k
being close to unity (k = 0.90, p >0.001 and k = 0.88, p
>0.001, respectively).
CMR with LGE
A commercially available gadolinium-based contrast agent,
gadodiamide (Omniscan, GE Healthcare, Amersham, UK),
was injected intravenously at a dose of 0.1 mmol/kg of
body weight, and 10-15 min after the injection CMR was
performed using a segmented inversion-recovery fast gradi-
ent echo sequence that has been described in detail pre-
viously [18]. LGE images were acquired in multiple short-
axis views identical to those obtained for cine CMR. The
planimetric analysis of LGE images was performed automa-
tically using the MASS-PLUS module of MRI-MASS soft-
ware (MEDIS, Leiden, NL). The software provides a semi-
automatic threshold tool that allows the identification of
pixels showing signal intensity higher than a pre-defined
threshold (> 2 standard deviations above normal myocar-
dium). The same 17-segment model was used with the area
of LGE enclosed by the epicardial and endocardial contours
measured in 6 basal, 6 mid-cavity and 4 apical segments
and the extent of LGE was defined as a percentage of LGE
area relative to total segment area [17]. Segments were
then graded semi-quantitatively using the following scale:
no LGE, 1% to 25%, 26% to 50%, 51% to 75%, and 76% to
100% of wall thickness. Visual estimation of LGE extent in
LV horizontal and vertical long-axis views was used for the
assessment of the 17th segment (apex).
Potentially viable but dysfunctional myocardial seg-
ments were defined as those with impaired thickening
but with ≤50% LGE [11]. A patient was classified as hav-
ing “substantial” myocardial viability if 5 or more such
segments were present.
Statistical analysis
Results are presented as median and interquartile range
(IQR) for continuous variables or as numbers
(percentages) for categorical variables. Comparisons
between sub-groups were made using the Mann-Whit-
ney U test for continuous variables and the chi-square
test for categorical variables. Linear regression analysis
and the Pearson correlation coefficient was apply to
examine the association between LVEF and the number
of dysfunctional segments. A P value < 0.05 was consid-
ered significant.
Results
Study subjects
Clinical characteristics of the study population are
shown in Table 2. Of 193 patients, only 129 (67%) had
suffered a clinically documented myocardial infarction
and 71 (37%) had undergone coronary revascularisation
prior to initial assessment. No patients had undergone
revascularisation between initial assessment and CMR
scanning. Co-morbidities, such as arterial hypertension
(resting systolic blood pressure > 140 mmHg or diastolic
> 90 mmHg or patients already under medical treatment
for elevated blood pressure) and diabetes mellitus, were
common. Most patients were receiving b-blockers and
RAAS inhibitors and had received this treatment for >
12 months prior to CMR.
On CMR, 186 patients had at least one dysfunctional
segment while seven patients had normal systolic func-
tion. LGE was observed in 169 (88%) patients. Substan-
tial myocardial viability, that is ≥5 dysfunctional
segments with ≤50% LGE, was found in 107 (55%)
patients of whom 49 (25%) had ≥5 dysfunctional seg-
ments with no scar and 25 (13%) patients also had ≥5
dysfunctional segments with > 50% LGE. 64 (33%)
patients had ≥5 dysfunctional segments with ≤25% scar
thickness. Dysfunctional segments without LGE were
not uncommon, with 104 patients (53%) having at least
one such segment (Figure 1).
Table 2 illustrates differences between the subgroups
of patients with and without substantial viability.
Patients with substantial viability had to have ≥5 dys-
functional segments, so the proportion of dysfunctional
segments was higher in this group than in those without
substantial viability (68% v 36%). Consequently, they had
more severe LV systolic dysfunction and dilation and
were less likely to tolerate treatment with a RAAS
Table 1 Intra- and interobserver variability for the left ventricular indices.
CMR measurements Intra-observer variability
(n = 30)
Inter-observer variability
(n = 30)
LVEF (%) 35.6 ± 9.1 0.1 ± 2.7 0.0 ± 2.1
LVEDV index (ml/m2) 121 ± 41 1.2 ± 3.7 -1.2 ± 1.3
LVESV index (ml/m2) 83 ± 38 0.6 ± 2.8 -1.0 ± 3.2
LVMM index (g/m2) 83 ± 22 1.4 ± 2.9 -0.3 ± 3.3
Results are presented as mean ± standard deviation
LV, left ventricle; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume index; MM, myocardial mass.
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inhibitor and a b-blocker. In other words, patients with
more severe LV dysfunction were more likely to have
substantial viability (Figure 2). On the other hand the
patients without substantial viability appeared to consti-
tute an inhomogeneous group. The subgroup of patients
with a LVEF below the median (< 41%) had a consider-
able proportion of scarred and dysfunctional myocar-
dium while the group with LVEF > 41% had few
segments with myocardial dysfunction or scar,
consistent with recovery of ventricular function in
response to medical therapy.
57 patients (29%) had ≥ 5 segments with scar thick-
ness > 50% but 2 out of 5 of them (24 patients) also had
≥ 5 dysfunctional segments with no or ≤ 50% partial
thickness scars. Compared to the other patients they
had lower LVEF (29% (22%-34%) v 37% (29%-45%), P <
0.0001) and increased LVEDV index (131 ml/m2 (112
ml/m2-173 ml/m2) v 114 ml/m2 (92 ml/m2-145 ml/m2),
Table 2 Characteristics of the patient population (n = 193).
All patients Absence of substantial viability Substantial Viability
(n = 193) All patients
(n = 86)
LVEF
< median
(n = 43)
LVEF
> median
(n = 43)
P1 (n = 107) P2
Age, years 70 (63-75) 69 (59-76) 69 (61-76) 66 (59-76) 0.534 70 (65-75) 0.283
Male sex 167 (87%) 77 (90%) 37 (86%) 40 (93%) 0.291 90 (84%) 0.273
BMI (kg/m2) 28 (25-31) 27 (25-31) 29 (25-32) 26 (24-30) 0.111 28 (25-31) 0.773
Systolic blood pressure mmHg) 123 (111-140) 132 (110-148) 117 (102-145) 136 (123-149) 0.002 120 (111-134) 0.084
Diastolic blood pressure (mmHg) 73 (65-80) 74 (64-84) 72 (61-80) 74 (66-86) 0.296 72 (65-80) 0.641
Heart rate (bpm) 65 (59-75) 63 (58-70) 64 (58-74) 62 (57-68) 0.308 66 (59-76) 0.057
NYHA classification 0.022 0.357
NYHA class I 32 (17%) 12 (14%) 3 (14%) 9 (21%) 20 (19%)
NYHA class II 124 (64%) 60 (70%) 29 (67%) 31 (72%) 64 (60%)
NYHA class III 37 (19%) 14 (16%) 11 (26%) 3 (7%) 23 (21%)
Previous infarct 129 (67%) 62 (72%) 34 (79%) 28 (65%) 0.149 67 (63%) 0.165
Previous revascularisation 71 (37%) 29 (34%) 15 (35%) 14 (33%) 0.820 42 (40%) 0.428
Co-morbidities:
History of hypertension 56 (29%) 24 (28%) 10 (23%) 14 (33%) 0.336 32 (30%) 0.761
Diabetes mellitus 36 (19%) 13 (15%) 5 (12%) 8 (19%) 0.366 23 (22%) 0.258
Medications:
b-blockers 167 (87%) 82 (95%) 42 (98%) 40 (93%) 0.306 85 (79%) 0.001
RAAS inhibitors 175 (91%) 83 (97%) 41 (95%) 42 (98%) 0.557 92 (86%) 0.012
Diuretics 130 (67%) 55 (64%) 30 (70%) 25 (58%) 0.261 75 (70%) 0.366
Spironolactone 53 (28%) 21 (24%) 16 (37%) 5 (12%) 0.006 32 (30%) 0.396
Digoxin 18 (9%) 6 (7%) 4 (9%) 2 (5%) 0.397 12 (10%) 0.314
CMR measurements
LVEF 34 (27-43) 41 (29-51) 29 (24-38) 50 (45-57) 31 (24-35) < 0.0001
LVEDV index 117 (95-150) 103 (84-127) 126 (101-155) 91 (69-104) < 0.0001 129 (111-156) < 0.0001
LVESV index 78 (55-110) 57 (41-83) 82 (69-113) 42 (32-54) < 0.0001 89 (72-117) < 0.0001
LVMM index 82 (71-101) 80 (68-97) 91 (73-106) 75 (65-84) 0.002 85 (74-101) 0.120
Segmental analysis
Segments 3281 1462 731 731 1819
Dysfunctional Segments 1759 (53%) 527 (36%) 154 (21%) 373 (51%) < 0.0001 1232 (68%)
Dysfunctional segments without LGE 581 (18%) 31 (2%) 14 (2%) 17 (2%) 0.884 550 (30%)
Dysfunctional segments with LGE 1178 (36%) 496 (34%) 140 (19%) 356 (49%) < 0.0001 682 (37%)
Dysfunctional segments with > 50% LGE 559 (17%) 313 (21%) 65 (9%) 248 (34%) < 0.0001 246 (14%)
Segments with normal function - no LGE 1326 (40%) 849 (58%) 513 (70%) 336 (46%) < 0.0001 477 (26%)
Segments with normal function and LGE 98 (3%) 43 (3%) 32 (4%) 11 (2%) 0.283 55 (3%)
Data are expressed as median and interquartile range (IQR) or as number and percentage (%) of patients.
P1 value represents the significance of differences between the subgroups of patients with no substantial viability and LVEF > median (41%) and those with LVEF
< median
P2 value expresses comparison between the groups with significant viability and no significant viability
LV, left ventricular; EF, ejection fraction; BMI, body mass index; NYHA, New York Heart Association; RAAS, rennin-angiotensin-aldosterone system; EDV, end-
diastolic volume; ESV, end-systolic volume; MM, myocardial mass; LGE, late gadolinium enhancement.
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P = 0.001) and LVESV index (94 ml/m2 (75 ml/m2-126
ml/m2) v 72 ml/m2 (51 ml/m2-100 ml/m2), P< 0.0001)
but there were no differences in the LVMM index (82
g/m2 (70 g/m2-97 g/m2) v 82 g/m2 (74 g/m2-101 g/m2),
P = 0.507).
The prevalence of LGE on a per segment basis is
shown in Figure 3. Half of the myocardial segments
were dysfunctional. Few segments with normal contrac-
tile function (6%) showed LGE (predominantly ≤25% of
wall thickness), while two thirds of segments with
Figure 1 Two Vein diagrams of which the first shows the presence of dysfunctional segments with > 50%, ≤50% and without late
gadolinium enhancement (LGE) (A), and the second the occurrence of ≥5 dysfunctional segments with > 50%, ≤50% and no LGE (B)
in the studied population.
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impaired function demonstrated at least some LGE. Of
1759 segments with contractile dysfunction, 581 had no
evidence of myocardial scar, 623 had ≤50%, and 555
segments had > 50% scar thickness.
Figure 4 shows the distribution of scar in the studied
population. Myocardial scars were more common in
apical and septal regions and less common in the LV
free wall (occurrence 54% v 25%, P = 0.002). These gra-
dients in distribution were true for partial thickness
(≤50% scar thickness) and extensive (> 50%) scars, but
more extreme for the latter group (25% v 7%, P =
0.030).
Figure 2 Associations between left ventricular ejection fraction (LVEF) and dysfunctional segments with ≤50% and > 50% scar
thickness.
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Discussion
There is still uncertainty as to the proportion of patients
with CHF due to IHD who have a substantial volume of
viable but dysfunctional myocardium and who might,
therefore have recoverable myocardial function. It is dif-
ficult to compare studies because they used different
imaging methods, different segmental models and differ-
ent definitions for the number of affected segments
required to declare a substantial problem. In previous
echocardiographic or radionuclide studies which speci-
fied that a substantial (e.g. 4/16 or 5/19 segments) num-
ber of such segments had to be present, the proportion
of patients with a substantial amount of viable but dys-
functional myocardium ranged from 27% to 61%
[7,19-21].
The inability of these techniques to distinguish the
relative amounts of scar and viable tissue may limit
their use in predicting the recovery of dysfunctional
myocardium in response to therapy. Nuclear imaging
methods detect viability by assessing perfusion, cell
membrane integrity and metabolism but have limited
spatial resolution and do not image scar directly [22].
Two small studies have compared the diagnostic accu-
racy of positron emission tomography and CMR with
LGE and one showed that the latter is superior to
nuclear imaging in detecting non-viable segments while
the other found no difference between the two techni-
ques [23,24]. No studies have compared the diagnostic
accuracy of stress echocardiography and CMR with LGE
but the CMR is likely to be superior in patients with
atrial fibrillation and in those with poor acoustic
windows [25]. In addition, there is pathological evidence
that hibernating tissue can lose its contractile apparatus
and therefore its ability to thicken in response to inotro-
pic stimuli [26]. Thus, echocardiography may not be as
reliable method as CMR in assessing myocardial viabi-
lity. In contrast, CMR supplemented by contrast studies
permits the accurate and reproducible assessment of
contractility and scar with a single imaging technique
[10-12].
Our study highlights the complexity of the myocardial
substrate in patients with CHF and IHD. Moderate to
severe contractile dysfunction was most commonly asso-
ciated with partial thickness scar, with slightly more
than half of the patients having five or more segments
affected. Contractile dysfunction in the absence of
underlying scar was also commonly observed, a distur-
bance of myocardial metabolism most likely induced by
ischaemia, hibernation or stunning. Finally, extensive (>
50%) scar was also frequent and affected one third
(32%) of the dysfunctional segments. There is likely to
be an added complexity in segments with partial thick-
ness scar, where contractile dysfunction will reflect not
only the extent of the scar but also the contractility of
the remaining myocardium. Ischaemia, hibernation and
stunning of the residual myocardium is likely to be
common in these segments.
Some meta-analyses have shown that revascularisation
in patients with viable myocardium improves outcome
[27]. On the other hand two randomised control trials
that have been recently published showed a neutral
effect of revascularisation on prognosis. Unfortunately,
Figure 3 Prevalence of myocardial segments with and without late gadolinium enhancement (LGE).
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the Heart Failure Revascularisation Trial (HEART) (in
which patients with LV systolic dysfunction and a sub-
stantial volume of viable myocardium were randomised
to medical treatment or revascularisation) was stopped
early due to problems with recruitment and funding
[28]. Only 138 patients were enrolled. There were no
differences in all cause mortality, quality of life or (in a
sub-study) systolic function as measured by CMR.
Figure 4 Scar distribution in the studied population (A), in the group without substantial viability (B) and in the group with
substantial viability (C). The black numbers correspond to the left ventricular (LV) segments with no late gadolinium enhancement (LGE), the
green to the segments with scar thickness ≤50% and the red to the segments with a scar thickness > 50%.
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However, the study was underpowered and thus the
final results needed to be further confirmed [29]. The
second trial, STICH (Surgical Treatment for Ischemic
Heart Failure), showed no effect of revascularisation on
death, but perhaps a modest effect on cardiovascular
death or hospitalisations [30]. A sub-study of STICH
trial examined the prognostic effect of revascularisation
in patients with substantial viability [31]. This included
601 patients (487 with substantial viable myocardium)
with a LVEF ≤35% who were followed-up for 5 years.
The reported results demonstrated that revascularisation
did not appear to improve outcomes (total mortality,
cardiovascular mortality or the combined end-point
total mortality/hospitalisation due to cardiovascular
causes). Though this sub-study provides evidence that
revascularisation has a neutral impact on hard end-
points it remains unclear whether it should be imple-
mented in patients suffering from CHF with substantial
viability to restore myocardial contractility, reduce heart
failure symptoms and improve quality of life.
Ultimately, assessing the extent to which LV dysfunc-
tion is due to myocardial scar may be more important
than trying to assess the potential for functional recov-
ery when assessing a patient for revascularisation. With
existing therapies, myocardial scar reflects irreversible
damage. Successful revascularisation might not only
eliminate myocardial ischaemia and stunning and resus-
citate hibernating myocardium but also reduce the risk
to viable myocardium, whether or not it is dysfunc-
tional, from further coronary occlusions. The potential
of attempted revascularisation to cause irreversible myo-
cardial damage, to which hibernating myocardial may be
more prone, should also be considered [32].
Our results may also be important for the selection of
patients for CRT. Extensive myocardial scar, perhaps
especially when it affects the postero-lateral wall of the
LV predicts a lower chance of recovery of ventricular
function with CRT [13,14]. This may reduce the func-
tional response to CRT but it is not clear whether it
also translates into a lesser impact in terms of prognosis
[33]. However, it is reassuring that transmural scar in
the postero-lateral wall was relatively uncommon in this
population as only 8% of the patients had scar > 50%
and only 4% of the patients had > 75% scar in this
region.
Limitations
There was a delay between the initial echocardiographic
assessment of cardiac function and CMR. During that
period, treatment with RAAS inhibitors and b-blockers
were initiated or increased, which may have led to
recovery of function in viable myocardial segments.
Accordingly, this report will underestimate the preva-
lence of viable but dysfunctional myocardial segments in
a treatment naïve population, although it is still a good
estimate of the proportion of segments with extensive
scar.
Although the evaluation of the contractile function of
the myocardial segments was based on wall thickness it
is possible that tethering or reciprocal changes caused
by neighboring dyssynchronous segments could lead to
inaccurate estimations. By convention, a myocardial seg-
ment was considered viable if ≤50% of the segment
showed LGE. However, a strict definition of “viability”
requires that the segment’s contractility improves after
revascularisation. As our patients are not routinely
revascularised in the absence of angina, we cannot be
certain that the segments we have labeled “viable” meet
this definition. Although available, the end-diastolic wall
thickness of the studied segments was not included in
our analysis as the conventional cut-off value of < 5.5
mm is not accurate in excluding functional recovery
after revascularisation [34,35]. A significant limitation of
this study is the absence of CMR with low-dose dobuta-
mine stress testing that would allow more reliable iden-
tification of segments that would improve their function
after revascularisation (especially in cases with inter-
mediate extent of scar tissue) [36].
We used the cut-off of 5 segments to define “substan-
tial” myocardial viability since observational studies show
that functional improvement following revascularisation
is more likely if a third of LV segments show contractile
dysfunction with viability [17]. However, recently Pegg et
al. demonstrated that myocardial recovery after revascu-
larisation depends not only on the number of the seg-
ments with partial scar thickness but also on the number
of the normal segments [6]. Considering that this was a
small study (only 33 patients were included) it has been
decided to use a cut-off (≥5 segments) value already
implemented in larger studies, albeit that these used
stress echocardiography to define substantial viability
[31,37,38]. We acknowledge the limitation of extrapolat-
ing this methodology to the present CMR based study
and recognize the need for further research to test and
refine these criteria preferably in the context of large ran-
domised trials of relevant interventions.
Conclusions
Viable but dysfunctional myocardial segments in
patients with CHF due to LV systolic dysfunction and
IHD remain common despite contemporary medical
therapy and frequently reflect two different pathologies,
partial thickness scar and contractile dysfunction, that
may have different prognostic and therapeutic implica-
tions. The extent of myocardial scar, which currently
reflects irreversible damage, may be a useful guide to
the likely extent of recovery of ventricular function with
pharmacological interventions and revascularisation.
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